Insider Selling: Nuvalent, Inc. (NASDAQ:NUVL) Director Sells 37,500 Shares of Stock

Nuvalent, Inc. (NASDAQ:NUVL - Get Free Report) Director Matthew Shair sold 37,500 shares of the company's stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $65.56, for a total transaction of $2,458,500.00. Following the completion of the transaction, the director now owns 1,574,698 shares of the company's stock, valued at $103,237,200.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Matthew Shair also recently made the following trade(s):

• On Monday, April 8th, Matthew Shair sold 37,500 shares of Nuvalent stock. The stock was sold at an average price of $68.44, for a total transaction of $2,566,500.00.
• On Monday, April 1st, Matthew Shair sold 37,500 shares of Nuvalent stock. The stock was sold at an average price of $76.92, for a total transaction of $2,884,500.00.
• On Monday, March 25th, Matthew Shair sold 37,500 shares of Nuvalent stock. The stock was sold at an average price of $76.77, for a total transaction of $2,878,875.00.

Nuvalent Stock Down 0.8 %

Nuvalent stock traded down $0.50 during mid-day trading on Wednesday, reaching $64.25. 587,403 shares of the company's stock traded hands, compared to its average volume of 432,178. The company has a market cap of $4.12 billion, a price-to-earnings ratio of -29.84 and a beta of 1.29. The stock has a 50 day moving average of $79.30 and a two-hundred day moving average of $70.66. Nuvalent, Inc. has a 12-month low of $29.25 and a 12-month high of $89.39.

Nuvalent (NASDAQ:NUVL - Get Free Report) last released its quarterly earnings results on Tuesday, February 27th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.02). As a group, sell-side analysts forecast that Nuvalent, Inc. will post -2.93 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Principal Financial Group Inc. increased its position in Nuvalent by 1.4% during the fourth quarter. Principal Financial Group Inc. now owns 9,774 shares of the company's stock valued at $719,000 after acquiring an additional 139 shares during the last quarter. Tower Research Capital LLC TRC increased its position in Nuvalent by 41.0% during the third quarter. Tower Research Capital LLC TRC now owns 643 shares of the company's stock valued at $30,000 after acquiring an additional 187 shares during the last quarter. State Board of Administration of Florida Retirement System increased its position in Nuvalent by 3.1% during the third quarter. State Board of Administration of Florida Retirement System now owns 7,020 shares of the company's stock valued at $323,000 after acquiring an additional 210 shares during the last quarter. Teacher Retirement System of Texas increased its position in Nuvalent by 4.8% during the third quarter. Teacher Retirement System of Texas now owns 5,846 shares of the company's stock valued at $269,000 after acquiring an additional 269 shares during the last quarter. Finally, Amalgamated Bank increased its position in Nuvalent by 8.1% during the fourth quarter. Amalgamated Bank now owns 3,815 shares of the company's stock valued at $281,000 after acquiring an additional 285 shares during the last quarter. Institutional investors own 97.26% of the company's stock.

Analysts Set New Price Targets

NUVL has been the topic of several research analyst reports. BMO Capital Markets boosted their target price on shares of Nuvalent from $93.00 to $102.00 and gave the stock an "outperform" rating in a report on Wednesday, February 28th. Wedbush reissued an "outperform" rating and issued a $99.00 target price on shares of Nuvalent in a report on Tuesday, February 27th. Guggenheim initiated coverage on shares of Nuvalent in a report on Wednesday, February 28th. They issued a "buy" rating and a $99.00 target price on the stock. JPMorgan Chase & Co. boosted their target price on shares of Nuvalent from $68.00 to $98.00 and gave the stock an "overweight" rating in a report on Wednesday, March 6th. Finally, Robert W. Baird initiated coverage on shares of Nuvalent in a report on Friday, February 23rd. They issued an "outperform" rating and a $105.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $90.78.

About Nuvalent

Nuvalent, Inc, a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.